Summary
Results for weight-loss drug targeting amylin find similar efficacy across different doses and high rates of side effects, raising questions about which dose Novo will pursue.
Source: STAT
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
